A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study | Zendy

AI Assistant Blog Pricing

<p>A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study</p>

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.